Alvotech's AVT23 is a biosimilar to Xolair.
3 reports, 0 independent
Updated Jun 26
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alvotech's AVT23 is a biosimilar to Xolair.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Alvotech's AVT23 is identified as a biosimilar to Xolair.
- Alvotech's Xolair biosimilar study achieved its primary endpoint.
- EMA recommended market approval for Alvotech's biosimilar.
Keep exploring
The entities involved
-
Alvotech
biotechnology company
Nothing else this week.
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet
- Unknown outlet